Skip to main content
Top
Published in: Familial Cancer 4/2018

01-10-2018 | Original Article

Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same

Authors: A. J. Huq, M. Walsh, B. Rajagopalan, M. Finlay, A. H. Trainer, F. Bonnet, N. Sevenet, I. M. Winship

Published in: Familial Cancer | Issue 4/2018

Login to get access

Abstract

Many cancer predisposition syndromes are preceded or accompanied by a range of typical skin signs. Gorlin syndrome is a rare multisystem inherited disorder which can predispose to basal cell carcinomas (BCCs), childhood medulloblastomas in addition to various developmental abnormalities; the majority of cases are due to mutations in the PTCH1 gene. Approximately 5% of cases have been attributed to a mutation in the SUFU gene. Certain phenotypic features have been identified as being more prevalent in individuals with a SUFU mutation such as childhood medulloblastoma, infundibulocystic BCCs and trichoepitheliomas. Recently hamartomatous skin lesions have also been noted in families with childhood medulloblastoma, a “Gorlin like” phenotype and a SUFU mutation. Here we describe a family previously diagnosed with Gorlin syndrome with a novel SUFU splice site deleterious genetic variant, who have several dermatological features including palmar sclerotic fibromas which has not been described in relation to a SUFU mutation before. We highlight the features more prominent in individuals with a SUFU mutation. It is important to note that emerging therapies for treatment of BCCs in patients with a PTCH1 mutation may not be effective in those with a SUFU mutation.
Literature
1.
go back to reference Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA (1993) Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 30(6):460–464CrossRef Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA (1993) Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 30(6):460–464CrossRef
2.
go back to reference Kimonis VE et al (1997) Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69(3):299–308CrossRef Kimonis VE et al (1997) Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69(3):299–308CrossRef
4.
go back to reference Epstein EH (2008) Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 8(10):743–754CrossRef Epstein EH (2008) Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 8(10):743–754CrossRef
6.
go back to reference Brugieres L, Remenieras A, Pierron G, Varlet P, Forget S, Byrde V, Bombled J, Puget S, Caron O, Dufour C, Delattre O, Bressac-de Paillerets B, Grill J (2012) High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 30(17):2087–2093. https://doi.org/10.1200/JCO.2011.38.7258 CrossRefPubMed Brugieres L, Remenieras A, Pierron G, Varlet P, Forget S, Byrde V, Bombled J, Puget S, Caron O, Dufour C, Delattre O, Bressac-de Paillerets B, Grill J (2012) High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 30(17):2087–2093. https://​doi.​org/​10.​1200/​JCO.​2011.​38.​7258 CrossRefPubMed
9.
go back to reference Smith MJ, Beetz C, Williams SG, Bhaskar SS, O’Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG (2014) Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32(36):4155–4161. https://doi.org/10.1200/JCO.2014.58.2569 CrossRefPubMed Smith MJ, Beetz C, Williams SG, Bhaskar SS, O’Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG (2014) Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32(36):4155–4161. https://​doi.​org/​10.​1200/​JCO.​2014.​58.​2569 CrossRefPubMed
16.
go back to reference Requena L, Farina MC, Robledo M, Sangueza OP, Sanchez E, Villanueva A, Marquina A, Tamarit R (1999) Multiple hereditary infundibulocystic basal cell carcinomas: a genodermatosis different from nevoid basal cell carcinoma syndrome. Arch Dermatol 135(10):1227–1235CrossRef Requena L, Farina MC, Robledo M, Sangueza OP, Sanchez E, Villanueva A, Marquina A, Tamarit R (1999) Multiple hereditary infundibulocystic basal cell carcinomas: a genodermatosis different from nevoid basal cell carcinoma syndrome. Arch Dermatol 135(10):1227–1235CrossRef
Metadata
Title
Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same
Authors
A. J. Huq
M. Walsh
B. Rajagopalan
M. Finlay
A. H. Trainer
F. Bonnet
N. Sevenet
I. M. Winship
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-018-0073-7

Other articles of this Issue 4/2018

Familial Cancer 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine